Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Breast Cancer

  Free Subscription

Articles published in Breast Cancer Res

Retrieve available abstracts of 286 articles:
HTML format

Single Articles

    November 2023
  1. GOKER M, Denys H, Hendrix A, De Wever O, et al
    Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
    Breast Cancer Res. 2023;25:146.
    PubMed     Abstract available

  2. VERSCHOOR N, Smid M, Jager A, Sleijfer S, et al
    Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
    Breast Cancer Res. 2023;25:145.
    PubMed     Abstract available

  3. SHARMA D, Hager CG, Shang L, Tran L, et al
    The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
    Breast Cancer Res. 2023;25:144.
    PubMed     Abstract available

  4. FRANCO-VALLS H, Tusquets-Uxo E, Sala L, Val M, et al
    Formation of an invasion-permissive matrix requires TGFbeta/SNAIL1-regulated alternative splicing of fibronectin.
    Breast Cancer Res. 2023;25:143.
    PubMed     Abstract available

  5. ASWOLINSKIY W, Munari E, Horlings HM, Mulder L, et al
    PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
    Breast Cancer Res. 2023;25:142.
    PubMed     Abstract available

  6. CAMPONE M, Bidard FC, Neven P, Wang L, et al
    AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
    Breast Cancer Res. 2023;25:141.
    PubMed     Abstract available

  7. BRACKENBURY WJ, Palmieri C
    Blocking channels to metastasis: targeting sodium transport in breast cancer.
    Breast Cancer Res. 2023;25:140.
    PubMed     Abstract available

  8. NIELSEN K, Sode M, Jensen MB, Berg T, et al
    High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients.
    Breast Cancer Res. 2023;25:139.
    PubMed     Abstract available

  9. KAZEROUNI AS, Peterson LM, Jenkins I, Novakova-Jiresova A, et al
    Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Breast Cancer Res. 2023;25:138.
    PubMed     Abstract available

  10. WEBSTER JL, Goldstein ND, Rowland JP, Tuite CM, et al
    A catchment and location-allocation analysis of mammography access in Delaware, US: implications for disparities in geographic access to breast cancer screening.
    Breast Cancer Res. 2023;25:137.
    PubMed     Abstract available

  11. HO PJ, Khng AJ, Tan BK, Lim GH, et al
    Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway.
    Breast Cancer Res. 2023;25:136.
    PubMed     Abstract available

  12. CHOI JE, Lee JS, Jin MS, Nikas IP, et al
    The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:134.
    PubMed     Abstract available

  13. MOKBEL K, Alamoodi M
    Exploring the interface zone in breast cancer: implications for surgical strategies and beyond.
    Breast Cancer Res. 2023;25:135.

  14. FLAQUE MCD, Galigniana NM, Beguelin W, Vicario R, et al
    Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
    Breast Cancer Res. 2023;25:133.

  15. YU Y, Ren W, He Z, Chen Y, et al
    Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study.
    Breast Cancer Res. 2023;25:132.
    PubMed     Abstract available

    October 2023
  16. BOUAMAR H, Broome LE, Lathrop KI, Jatoi I, et al
    mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers.
    Breast Cancer Res. 2023;25:131.
    PubMed     Abstract available

  17. BUSUND M, Ursin G, Lund E, Wilsgaard T, et al
    Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer.
    Breast Cancer Res. 2023;25:130.
    PubMed     Abstract available

  18. ZHANG H, Gao M, Zhao W, Yu L, et al
    The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation.
    Breast Cancer Res. 2023;25:129.
    PubMed     Abstract available

  19. YE Z, Nguyen TL, Dite GS, MacInnis RJ, et al
    Causal relationships between breast cancer risk factors based on mammographic features.
    Breast Cancer Res. 2023;25:127.
    PubMed     Abstract available

  20. JUNG J, Kim NH, Kwon M, Park J, et al
    The inhibitory effect of Gremlin-2 on adipogenesis suppresses breast cancer cell growth and metastasis.
    Breast Cancer Res. 2023;25:128.
    PubMed     Abstract available

  21. ZHU S, Zhang M, Liu X, Luo Q, et al
    Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer.
    Breast Cancer Res. 2023;25:126.
    PubMed     Abstract available

  22. RAMESSUR A, Ambasager B, Valle Aramburu I, Peakman F, et al
    Circulating neutrophils from patients with early breast cancer have distinct subtype-dependent phenotypes.
    Breast Cancer Res. 2023;25:125.
    PubMed     Abstract available

  23. LIU C, Lu C, Yixi L, Hong J, et al
    Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
    Breast Cancer Res. 2023;25:124.
    PubMed     Abstract available

  24. SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al
    Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Breast Cancer Res. 2023;25:123.
    PubMed     Abstract available

  25. Symposium Mammographicum 2023.
    Breast Cancer Res. 2023;25.

  26. GETZ KR, Jeon MS, Luo C, Luo J, et al
    Lipidome of mammographic breast density in premenopausal women.
    Breast Cancer Res. 2023;25:121.
    PubMed     Abstract available

  27. BROEKER CD, Ortiz MMO, Murillo MS, Andrechek ER, et al
    Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
    Breast Cancer Res. 2023;25:120.
    PubMed     Abstract available

  28. JONAS K, Prinz F, Ferracin M, Krajina K, et al
    MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
    Breast Cancer Res. 2023;25:119.
    PubMed     Abstract available

  29. ZHOU L, Wu J, Ruan M, Xiao Y, et al
    The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.
    Breast Cancer Res. 2023;25:115.
    PubMed     Abstract available

  30. STEENBRUGGEN TG, Wolf DM, Campbell MJ, Sanders J, et al
    B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Breast Cancer Res. 2023;25:117.
    PubMed     Abstract available

  31. OLINDER J, Johnson K, Akesson A, Fornvik D, et al
    Impact of breast density on diagnostic accuracy in digital breast tomosynthesis versus digital mammography: results from a European screening trial.
    Breast Cancer Res. 2023;25:116.
    PubMed     Abstract available

  32. WATSON J, Wang T, Ho KL, Feng Y, et al
    Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
    Breast Cancer Res. 2023;25:114.
    PubMed     Abstract available

  33. QI X, Shi Q, Xuhong J, Zhang Y, et al
    Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
    Breast Cancer Res. 2023;25:113.
    PubMed     Abstract available

  34. DUNLOP HM, Williams LJ, Hall PS, Barber M, et al
    Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland.
    Breast Cancer Res. 2023;25:106.
    PubMed     Abstract available

  35. ZOLLNER L, Torres D, Briceno I, Gilbert M, et al
    Native American ancestry and breast cancer risk in Colombian and Mexican women: ruling out potential confounding through ancestry-informative markers.
    Breast Cancer Res. 2023;25:111.
    PubMed     Abstract available

  36. GERRATANA L, Davis AA, Velimirovic M, Clifton K, et al
    Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Breast Cancer Res. 2023;25:112.
    PubMed     Abstract available

    September 2023
  37. LUNDGREN C, Tutzauer J, Church SE, Stal O, et al
    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
    Breast Cancer Res. 2023;25:110.
    PubMed     Abstract available

  38. LUO D, Liang Y, Wang Y, Ye F, et al
    Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD.
    Breast Cancer Res. 2023;25:109.
    PubMed     Abstract available

  39. ZAHL PH
    Re: Non-progressive breast carcinomas detected at mammography screening: a population study-a model test or a novel test of cancer regression?
    Breast Cancer Res. 2023;25:108.

  40. JAN R, Huang M, Lewis-Wambi J
    Retraction Note: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Breast Cancer Res. 2023;25:107.

  41. SUNDEN M, Norgren S, Lundqvist R, Andersson A, et al
    Receptor conversion and survival in breast cancer liver metastases.
    Breast Cancer Res. 2023;25:105.
    PubMed     Abstract available

  42. BLYTH RRR, Birts CN, Beers SA
    The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancer.
    Breast Cancer Res. 2023;25:104.
    PubMed     Abstract available

    August 2023
  43. NEVEN P, Fasching PA, Chia S, Jerusalem G, et al
    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Breast Cancer Res. 2023;25:103.
    PubMed     Abstract available

  44. HAPACH LA, Wang W, Schwager SC, Pokhriyal D, et al
    Phenotypically sorted highly and weakly migratory triple negative breast cancer cells exhibit migratory and metastatic commensalism.
    Breast Cancer Res. 2023;25:102.
    PubMed     Abstract available

  45. LOFLING LL, Stoer NC, Andreassen BK, Ursin G, et al
    Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
    Breast Cancer Res. 2023;25:101.
    PubMed     Abstract available

  46. YANG W, Xu M, Xu S, Guan Q, et al
    Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors.
    Breast Cancer Res. 2023;25:100.
    PubMed     Abstract available

  47. CASTILLO-CASTREJON M, Sankofi BM, Murguia SJ, Udeme AA, et al
    FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
    Breast Cancer Res. 2023;25:99.
    PubMed     Abstract available

  48. LIU S, Chen W, Hu H, Zhang T, et al
    Correction: Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2023;25:98.

  49. ABUBAKAR M, Klein A, Fan S, Lawrence S, et al
    Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.
    Breast Cancer Res. 2023;25:97.
    PubMed     Abstract available

  50. ZHOU F, Yang G, Xue L, Liu Y, et al
    SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Breast Cancer Res. 2023;25:96.
    PubMed     Abstract available

  51. DEROUEN MC, Yang J, Li Y, Franke AA, et al
    Circulating 27-hydroxycholesterol, lipids, and steroid hormones in breast cancer risk: a nested case-control study of the Multiethnic Cohort Study.
    Breast Cancer Res. 2023;25:95.
    PubMed     Abstract available

  52. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:94.

  53. MIDDHA P, Wang X, Behrens S, Bolla MK, et al
    A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
    Breast Cancer Res. 2023;25:93.
    PubMed     Abstract available

  54. HABEL LA, Alexeeff SE, Achacoso N, Arasu VA, et al
    Examination of fully automated mammographic density measures using LIBRA and breast cancer risk in a cohort of 21,000 non-Hispanic white women.
    Breast Cancer Res. 2023;25:92.
    PubMed     Abstract available

  55. MARTINEZ-ILLESCAS NG, Leal S, Gonzalez P, Grana-Castro O, et al
    miR-203 drives breast cancer cell differentiation.
    Breast Cancer Res. 2023;25:91.
    PubMed     Abstract available

    July 2023
  56. DAI H, Xu W, Wang L, Li X, et al
    Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development.
    Breast Cancer Res. 2023;25:90.
    PubMed     Abstract available

  57. MOHL A, Behrens S, Flasskamp F, Obi N, et al
    The impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study.
    Breast Cancer Res. 2023;25:89.
    PubMed     Abstract available

  58. ZHENG C, Xu X, Wu M, Xue L, et al
    Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance.
    Breast Cancer Res. 2023;25:88.
    PubMed     Abstract available

  59. ADAM R, Dell'Aquila K, Hodges L, Maldjian T, et al
    Deep learning applications to breast cancer detection by magnetic resonance imaging: a literature review.
    Breast Cancer Res. 2023;25:87.
    PubMed     Abstract available

  60. CHUANGCHOT N, Jamjuntra P, Yangngam S, Luangwattananun P, et al
    Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
    Breast Cancer Res. 2023;25:86.
    PubMed     Abstract available

  61. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:84.
    PubMed     Abstract available

  62. XIA W, Chen W, Ni C, Meng X, et al
    Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.
    Breast Cancer Res. 2023;25:85.
    PubMed     Abstract available

  63. SMOTHERMAN C, Sprague B, Datta S, Braithwaite D, et al
    Association of air pollution with postmenopausal breast cancer risk in UK Biobank.
    Breast Cancer Res. 2023;25:83.
    PubMed     Abstract available

  64. GERMAN R, Marino N, Hemmerich C, Podicheti R, et al
    Exploring breast tissue microbial composition and the association with breast cancer risk factors.
    Breast Cancer Res. 2023;25:82.
    PubMed     Abstract available

  65. ZHANG J, McAndrew NP, Wang X, Du Y, et al
    Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
    Breast Cancer Res. 2023;25:81.
    PubMed     Abstract available

  66. HEGGLAND T, Vatten LJ, Opdahl S, Weedon-Fekjaer H, et al
    Non-progressive breast carcinomas detected at mammography screening: a population study.
    Breast Cancer Res. 2023;25:80.
    PubMed     Abstract available

    June 2023
  67. PARK AY, Han MR, Seo BK, Ju HY, et al
    MRI-based breast cancer radiogenomics using RNA profiling: association with subtypes in a single-center prospective study.
    Breast Cancer Res. 2023;25:79.
    PubMed     Abstract available

  68. ALVES DA COSTA F, Cardoso Borges F, Ramos A, Mayer A, et al
    Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice.
    Breast Cancer Res. 2023;25:78.
    PubMed     Abstract available

  69. TENG X, Zhang J, Zhang X, Fan X, et al
    Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:77.
    PubMed     Abstract available

  70. KATZENELLENBOGEN BS, Guillen VS, Katzenellenbogen JA
    Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Breast Cancer Res. 2023;25:76.
    PubMed     Abstract available

  71. ZHANG Y, Lv L, Zheng R, Xie R, et al
    Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
    Breast Cancer Res. 2023;25:75.
    PubMed     Abstract available

  72. Meeting Abstracts from the British Society of Breast Radiology Annual Scientific Meeting 2022.
    Breast Cancer Res. 2023;25.

  73. KAST K, John EM, Hopper JL, Andrieu N, et al
    Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.
    Breast Cancer Res. 2023;25:72.
    PubMed     Abstract available

  74. LIEFAARD MC, van der Voort A, van Ramshorst MS, Sanders J, et al
    BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
    Breast Cancer Res. 2023;25:71.
    PubMed     Abstract available

  75. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    Correction to: National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:70.

  76. ANDERSEN LVB, Larsen MJ, Davies H, Degasperi A, et al
    Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness.
    Breast Cancer Res. 2023;25:69.
    PubMed     Abstract available

  77. O'LEARY KA, Bates AM, Jin WJ, Burkel BM, et al
    Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    Breast Cancer Res. 2023;25:68.
    PubMed     Abstract available

  78. SCHMID P, Cortes J, Joaquim A, Janez NM, et al
    XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
    Breast Cancer Res. 2023;25:67.
    PubMed     Abstract available

  79. YOUNG KL, Olshan AF, Lunetta K, Graff M, et al
    Influence of alcohol consumption and alcohol metabolism variants on breast cancer risk among Black women: results from the AMBER consortium.
    Breast Cancer Res. 2023;25:66.
    PubMed     Abstract available

  80. ILLIPSE M, Czene K, Hall P, Humphreys K, et al
    Studying the association between longitudinal mammographic density measurements and breast cancer risk: a joint modelling approach.
    Breast Cancer Res. 2023;25:64.
    PubMed     Abstract available

  81. FERRONI G, Sabeti S, Abdus-Shakur T, Scalise L, et al
    Noninvasive prediction of axillary lymph node breast cancer metastasis using morphometric analysis of nodal tumor microvessels in a contrast-free ultrasound approach.
    Breast Cancer Res. 2023;25:65.
    PubMed     Abstract available

  82. YANG C, Liu J, Zhao S, Shang Q, et al
    Infiltrating myeloid cell diversity determines oncological characteristics and clinical outcomes in breast cancer.
    Breast Cancer Res. 2023;25:63.
    PubMed     Abstract available

  83. LIU S, Xie SM, Liu W, Gagea M, et al
    Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
    Breast Cancer Res. 2023;25:62.
    PubMed     Abstract available

    May 2023
  84. XU JB, Cao J, Xia J, Zhu Y, et al
    Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA.
    Breast Cancer Res. 2023;25:59.
    PubMed     Abstract available

  85. COELINGH BENNINK HJT, Schultz IJ, Schmidt M, Jordan VC, et al
    Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.
    Breast Cancer Res. 2023;25:60.
    PubMed     Abstract available

  86. LANG M, Liang P, Shen H, Li H, et al
    Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study.
    Breast Cancer Res. 2023;25:61.
    PubMed     Abstract available

  87. MIYASHITA M, Bell JSK, Wenric S, Karaesmen E, et al
    Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
    Breast Cancer Res. 2023;25:58.
    PubMed     Abstract available

  88. TANG X, Thompson KJ, Kalari KR, Sinnwell JP, et al
    Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
    Breast Cancer Res. 2023;25:57.
    PubMed     Abstract available

  89. HOFFMANN E, Gerwing M, Krahling T, Hansen U, et al
    Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Breast Cancer Res. 2023;25:56.
    PubMed     Abstract available

  90. QI M, Yi X, Yue B, Huang M, et al
    S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
    Breast Cancer Res. 2023;25:55.
    PubMed     Abstract available

  91. PETERSON JR, Cole JA, Pfeiffer JR, Norris GH, et al
    Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Breast Cancer Res. 2023;25:54.
    PubMed     Abstract available

  92. SMID M, Schmidt MK, Prager-van der Smissen WJC, Ruigrok-Ritstier K, et al
    Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Breast Cancer Res. 2023;25:53.
    PubMed     Abstract available

  93. VAN DER NOORD VE, van der Stel W, Louwerens G, Verhoeven D, et al
    Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    Breast Cancer Res. 2023;25:51.
    PubMed     Abstract available

  94. RAMIN C, Veiga LHS, Vo JB, Curtis RE, et al
    Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
    Breast Cancer Res. 2023;25:50.
    PubMed     Abstract available

    April 2023
  95. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:47.
    PubMed     Abstract available

  96. ZHANG J, Qin Z, So TH, Chang TY, et al
    Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial.
    Breast Cancer Res. 2023;25:49.
    PubMed     Abstract available

  97. RAGU ME, Lim JMC, Ng PS, Yip CH, et al
    TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
    Breast Cancer Res. 2023;25:48.
    PubMed     Abstract available

  98. LEE S, Toft NJ, Axelsen TV, Espejo MS, et al
    Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer.
    Breast Cancer Res. 2023;25:46.
    PubMed     Abstract available

  99. COHEN SY, Stoll CR, Anandarajah A, Doering M, et al
    Modifiable risk factors in women at high risk of breast cancer: a systematic review.
    Breast Cancer Res. 2023;25:45.
    PubMed     Abstract available

  100. MANI C, Acharya G, Saamarthy K, Ochola D, et al
    Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:44.
    PubMed     Abstract available

  101. LIU H, Yan R, Xiao Z, Huang X, et al
    Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Breast Cancer Res. 2023;25:43.
    PubMed     Abstract available

  102. LE CORNET C, Jung AY, Johnson TS, Behrens S, et al
    Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort.
    Breast Cancer Res. 2023;25:42.
    PubMed     Abstract available

  103. ZHANG X, Gunda A, Kranenbarg EM, Liefers GJ, et al
    Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
    Breast Cancer Res. 2023;25:40.
    PubMed     Abstract available

  104. MURAKAMI-NISHIMAGI Y, Sugimoto K, Kobayashi M, Tachibana K, et al
    Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor beta.
    Breast Cancer Res. 2023;25:41.
    PubMed     Abstract available

  105. BLISS JM, Tovey H, Evans A, Holcombe C, et al
    Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
    Breast Cancer Res. 2023;25:39.
    PubMed     Abstract available

  106. ZHANG F, Zheng Z, Wang L, Zeng W, et al
    PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta1 overcomes radiotherapy resistance in breast cancer.
    Breast Cancer Res. 2023;25:38.
    PubMed     Abstract available

  107. JANEVA S, Krabbe E, Parris TZ, Nasic S, et al
    Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer.
    Breast Cancer Res. 2023;25:36.
    PubMed     Abstract available

  108. DURAN CL, Karagiannis GS, Chen X, Sharma VP, et al
    Cooperative NF-kappaB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer.
    Breast Cancer Res. 2023;25:37.
    PubMed     Abstract available

    March 2023
  109. MASALA G, Bendinelli B, Caini S, Duroni G, et al
    Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study.
    Breast Cancer Res. 2023;25:35.
    PubMed     Abstract available

  110. HU XE, Yang P, Chen S, Wei G, et al
    Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
    Breast Cancer Res. 2023;25:34.
    PubMed     Abstract available

  111. YAGHJYAN L, Heng YJ, Baker GM, Rosner BA, et al
    Associations of alcohol consumption with breast tissue composition.
    Breast Cancer Res. 2023;25:33.
    PubMed     Abstract available

  112. WIMBERGER P, Blohmer JU, Krabisch P, Link T, et al
    The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Breast Cancer Res. 2023;25:32.
    PubMed     Abstract available

  113. ROLLAND AL, Porro B, Kab S, Ribet C, et al
    Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES).
    Breast Cancer Res. 2023;25:30.
    PubMed     Abstract available

  114. WANG W, Rana PS, Markovic V, Sossey-Alaoui K, et al
    The WAVE3/beta-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
    Breast Cancer Res. 2023;25:31.
    PubMed     Abstract available

  115. GUNNARSDOTTIR FB, Bendahl PO, Johansson A, Benfeitas R, et al
    Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Breast Cancer Res. 2023;25:29.
    PubMed     Abstract available

  116. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:28.

  117. TUNALI G, Yanik H, Ozturk SC, Demirkol-Canli S, et al
    A positive feedback loop driven by fibronectin and IL-1beta sustains the inflammatory microenvironment in breast cancer.
    Breast Cancer Res. 2023;25:27.
    PubMed     Abstract available

  118. PECAR G, Liu S, Hooda J, Atkinson JM, et al
    RET signaling in breast cancer therapeutic resistance and metastasis.
    Breast Cancer Res. 2023;25:26.
    PubMed     Abstract available

  119. CHAUDHARY S, Appadurai MI, Maurya SK, Nallasamy P, et al
    MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
    Breast Cancer Res. 2023;25:25.
    PubMed     Abstract available

  120. HATHAWAY CA, Rice MS, Collins LC, Chen D, et al
    Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
    Breast Cancer Res. 2023;25:24.
    PubMed     Abstract available

    February 2023
  121. CHEN ZH, Tian Y, Zhou GL, Yue HR, et al
    CMTM7 inhibits breast cancer progression by regulating Wnt/beta-catenin signaling.
    Breast Cancer Res. 2023;25:22.
    PubMed     Abstract available

  122. SAEKI S, Kumegawa K, Takahashi Y, Yang L, et al
    Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
    Breast Cancer Res. 2023;25:21.
    PubMed     Abstract available

  123. LEE ES, Kim Y, Shin HC, Hwang KT, et al
    Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial.
    Breast Cancer Res. 2023;25:20.
    PubMed     Abstract available

  124. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
    Breast Cancer Res. 2023;25:18.
    PubMed     Abstract available

  125. OUYANG D, Hong T, Fu M, Li Y, et al
    METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Breast Cancer Res. 2023;25:19.
    PubMed     Abstract available

  126. CHOWDHURY A, Pharoah PD, Rueda OM
    Evaluation and comparison of different breast cancer prognosis scores based on gene expression data.
    Breast Cancer Res. 2023;25:17.
    PubMed     Abstract available

  127. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Correction: Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:16.

  128. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    Correction: A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:15.

    January 2023
  129. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:13.
    PubMed     Abstract available

  130. AYENI OA, Jofe M, Mapanga W, Chen WC, et al
    Correction: Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:14.

  131. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:12.
    PubMed     Abstract available

  132. LIEN HC, Hsu CL, Lu YS, Chen TW, et al
    Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
    Breast Cancer Res. 2023;25:11.
    PubMed     Abstract available

  133. LIU Z, Choksi S, Kwon HJ, Jiao D, et al
    Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity.
    Breast Cancer Res. 2023;25:10.
    PubMed     Abstract available

  134. SCHONBERG MA, Wolfson EA, Eliassen AH, Bertrand KA, et al
    A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old.
    Breast Cancer Res. 2023;25:8.
    PubMed     Abstract available

  135. WANG Y, Liu F, Sun L, Jia Y, et al
    Association between human blood metabolome and the risk of breast cancer.
    Breast Cancer Res. 2023;25:9.
    PubMed     Abstract available

  136. AYENI OA, Joffe M, Mapanga W, Chen WC, et al
    Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:7.
    PubMed     Abstract available

  137. TODHUNTER ME, Miyano M, Carlson EG, Hinz S, et al
    Sustained postconfluent culture of human mammary epithelial cells enriches for luminal and c-Kit+ subtypes.
    Breast Cancer Res. 2023;25:6.
    PubMed     Abstract available

  138. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:5.
    PubMed     Abstract available

  139. CAO Z, Liu R, Li Y, Luo X, et al
    MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer.
    Breast Cancer Res. 2023;25:3.
    PubMed     Abstract available

  140. KIM CG, Kim MH, Kim JH, Kim SG, et al
    On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
    Breast Cancer Res. 2023;25:4.
    PubMed     Abstract available

  141. DE HAAS SL, Slamon DJ, Martin M, Press MF, et al
    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    Breast Cancer Res. 2023;25:2.
    PubMed     Abstract available

  142. CHEN S, Paul MR, Sterner CJ, Belka GK, et al
    PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
    Breast Cancer Res. 2023;25:1.
    PubMed     Abstract available

    December 2022
  143. ANANDARAJAH A, Chen Y, Colditz GA, Hardi A, et al
    Studies of parenchymal texture added to mammographic breast density and risk of breast cancer: a systematic review of the methods used in the literature.
    Breast Cancer Res. 2022;24:101.
    PubMed     Abstract available

  144. SHAH JS, Milevskiy MJG, Petrova V, Au AYM, et al
    Towards resolution of the intron retention paradox in breast cancer.
    Breast Cancer Res. 2022;24:100.
    PubMed     Abstract available

  145. LUO J, Zou H, Guo Y, Tong T, et al
    SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
    Breast Cancer Res. 2022;24:99.
    PubMed     Abstract available

  146. YADAV N, Sunder R, Desai S, Dharavath B, et al
    Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer.
    Breast Cancer Res. 2022;24:97.
    PubMed     Abstract available

  147. JOE NS, Godet I, Milki N, Ain NUI, et al
    Mebendazole prevents distant organ metastases in part by decreasing ITGbeta4 expression and cancer stemness.
    Breast Cancer Res. 2022;24:98.
    PubMed     Abstract available

  148. LEE ARGOV EJ, Rodriguez CB, Agovino M, Wei Y, et al
    Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort.
    Breast Cancer Res. 2022;24:95.
    PubMed     Abstract available

  149. KIM S, Tran TXM, Song H, Park B, et al
    Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study.
    Breast Cancer Res. 2022;24:96.
    PubMed     Abstract available

  150. FERNANDEZ G, Prastawa M, Madduri AS, Scott R, et al
    Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years.
    Breast Cancer Res. 2022;24:93.
    PubMed     Abstract available

  151. PAN Y, Yang Y, Huang R, Yang H, et al
    Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors.
    Breast Cancer Res. 2022;24:92.
    PubMed     Abstract available

  152. SIRVEN P, Faucheux L, Grandclaudon M, Michea P, et al
    Definition of a novel breast tumor-specific classifier based on secretome analysis.
    Breast Cancer Res. 2022;24:94.
    PubMed     Abstract available

  153. DORGAN JF, Baer HJ, Bertrand KA, LeBlanc ES, et al
    Childhood adiposity, serum metabolites and breast density in young women.
    Breast Cancer Res. 2022;24:91.
    PubMed     Abstract available

  154. SGROI DC, Treuner K, Zhang Y, Piper T, et al
    Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Breast Cancer Res. 2022;24:90.
    PubMed     Abstract available

  155. YAGHJYAN L, Eliassen AH, Colditz G, Rosner B, et al
    Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
    Breast Cancer Res. 2022;24:89.
    PubMed     Abstract available

  156. SEMINA SE, Alejo LH, Chopra S, Kansara NS, et al
    Identification of a novel ER-NFkB-driven stem-like cell population associated with relapse of ER+ breast tumors.
    Breast Cancer Res. 2022;24:88.
    PubMed     Abstract available

  157. HASSAINE Y, Jacquet E, Seigneurin A, Delafosse P, et al
    Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?
    Breast Cancer Res. 2022;24:87.
    PubMed     Abstract available

  158. DAVIS LYNN BC, Lord BD, Cora R, Pfeiffer RM, et al
    Associations between quantitative measures of TDLU involution and breast tumor molecular subtypes among breast cancer cases in the Black Women's Health Study: a case-case analysis.
    Breast Cancer Res. 2022;24:86.
    PubMed     Abstract available

    November 2022
  159. GU J, Ternifi R, Sabeti S, Larson NB, et al
    Volumetric imaging and morphometric analysis of breast tumor angiogenesis using a new contrast-free ultrasound technique: a feasibility study.
    Breast Cancer Res. 2022;24:85.
    PubMed     Abstract available

  160. PHILIPPSON C, Larsen S, Simon S, Vandekerkhove C, et al
    Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
    Breast Cancer Res. 2022;24:83.
    PubMed     Abstract available

  161. BALLINGER TJ, Thompson WR, Guise TA
    The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health.
    Breast Cancer Res. 2022;24:84.
    PubMed     Abstract available

  162. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:82.

  163. WU L, Ye W, Liu Y, Chen D, et al
    An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study.
    Breast Cancer Res. 2022;24:81.
    PubMed     Abstract available

  164. BALLOT E, Galland L, Mananet H, Boidot R, et al
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Breast Cancer Res. 2022;24:80.
    PubMed     Abstract available

  165. KOLYVAS EA, Caldas C, Kelly K, Ahmad SS, et al
    Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Breast Cancer Res. 2022;24:79.
    PubMed     Abstract available

  166. ASAD S, Damicis A, Heng YJ, Kananen K, et al
    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
    Breast Cancer Res. 2022;24:78.
    PubMed     Abstract available

  167. PEDERSEN DC, Jensen BW, Tjonneland A, Andersen ZJ, et al
    Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes.
    Breast Cancer Res. 2022;24:77.
    PubMed     Abstract available

  168. SZABOVA L, Gordon MB, Lu L, Pate N, et al
    Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Breast Cancer Res. 2022;24:75.
    PubMed     Abstract available

  169. CRAGER M, Wijayawardana SR, Gruver AM, Blacklock A, et al
    Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score(R) result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
    Breast Cancer Res. 2022;24:74.
    PubMed     Abstract available

    October 2022
  170. HAN SJ, Sung N, Wang J, O'Malley BW, et al
    Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
    Breast Cancer Res. 2022;24:73.
    PubMed     Abstract available

  171. KARTHIKEYAN S, Casey PJ, Wang M
    RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation.
    Breast Cancer Res. 2022;24:72.
    PubMed     Abstract available

  172. LA VERDE N, Damia G, Garrone O, Santini D, et al
    Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    Breast Cancer Res. 2022;24:71.
    PubMed     Abstract available

  173. DU T, Pan L, Zheng C, Chen K, et al
    Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Breast Cancer Res. 2022;24:70.
    PubMed     Abstract available

  174. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    PubMed     Abstract available

  175. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    PubMed     Abstract available

  176. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    PubMed     Abstract available

  177. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    PubMed     Abstract available

  178. LUCHTENBORG AM, Metzger P, Cosenza Contreras M, Oria V, et al
    Kruppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.
    Breast Cancer Res. 2022;24:65.
    PubMed     Abstract available

    September 2022
  179. ZIOLKOWSKI P, Wozniak M, Mansour A, An Y, et al
    Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
    Breast Cancer Res. 2022;24:64.
    PubMed     Abstract available

  180. DENG N, Minoche A, Harvey K, Li M, et al
    Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
    Breast Cancer Res. 2022;24:63.
    PubMed     Abstract available

  181. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    PubMed     Abstract available

  182. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    PubMed     Abstract available

  183. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    PubMed     Abstract available

  184. DUGUE PA, Bodelon C, Chung FF, Brewer HR, et al
    Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.
    Breast Cancer Res. 2022;24:59.
    PubMed     Abstract available

  185. KOLBERG-LIEDTKE C, Feuerhake F, Garke M, Christgen M, et al
    Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Breast Cancer Res. 2022;24:58.
    PubMed     Abstract available

    August 2022
  186. LIU C, Hu S, Xu X, Zhang Y, et al
    Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
    Breast Cancer Res. 2022;24:57.
    PubMed     Abstract available

  187. CLARKE S, Chin SN, Dodds L, George SHL, et al
    Racial disparities in breast cancer preclinical and clinical models.
    Breast Cancer Res. 2022;24:56.
    PubMed     Abstract available

    July 2022
  188. JONES LI, Marshall A, Elangovan P, Geach R, et al
    Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset.
    Breast Cancer Res. 2022;24:55.
    PubMed     Abstract available

  189. LEE S, Osmanbeyoglu HU
    Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
    Breast Cancer Res. 2022;24:54.
    PubMed     Abstract available

  190. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2022;24:53.

  191. HANNA A, Nixon MJ, Estrada MV, Sanchez V, et al
    Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Breast Cancer Res. 2022;24:51.
    PubMed     Abstract available

  192. SALVATI A, Melone V, Sellitto A, Rizzo F, et al
    Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Breast Cancer Res. 2022;24:52.
    PubMed     Abstract available

  193. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2022;24:50.

  194. WARD SV, Burton A, Tamimi RM, Pereira A, et al
    The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density.
    Breast Cancer Res. 2022;24:49.
    PubMed     Abstract available

  195. MIR S, Golden BDO, Griess BJ, Vengoji R, et al
    Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
    Breast Cancer Res. 2022;24:48.
    PubMed     Abstract available

  196. AL-TWEIGERI T, AlRaouji NN, Tulbah A, Arafah M, et al
    High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
    Breast Cancer Res. 2022;24:46.
    PubMed     Abstract available

  197. KEHM RD, Walter EJ, Oskar S, White ML, et al
    Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study.
    Breast Cancer Res. 2022;24:47.
    PubMed     Abstract available

  198. OGONY J, de Bel T, Radisky DC, Kachergus J, et al
    Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.
    Breast Cancer Res. 2022;24:45.
    PubMed     Abstract available

    June 2022
  199. WAGNER KU
    Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
    Breast Cancer Res. 2022;24:44.

  200. PEDERSEN CA, Cao MD, Fleischer T, Rye MB, et al
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Breast Cancer Res. 2022;24:43.
    PubMed     Abstract available

  201. WELLBERG EA, Corleto KA, Checkley LA, Jindal S, et al
    Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Breast Cancer Res. 2022;24:42.
    PubMed     Abstract available

  202. RATZ L, Brambillasca C, Bartke L, Huetzen MA, et al
    Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Breast Cancer Res. 2022;24:41.
    PubMed     Abstract available

  203. CARR D, Zein A, Coulombe J, Jiang T, et al
    Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.
    Breast Cancer Res. 2022;24:40.
    PubMed     Abstract available

  204. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    PubMed     Abstract available

  205. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    PubMed     Abstract available

  206. SIEGEL SD, Brooks MM, Lynch SM, Sims-Mourtada J, et al
    Racial disparities in triple negative breast cancer: toward a causal architecture approach.
    Breast Cancer Res. 2022;24:37.
    PubMed     Abstract available

    May 2022
  207. KOEVOETS EW, Schagen SB, de Ruiter MB, Geerlings MI, et al
    Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
    Breast Cancer Res. 2022;24:36.
    PubMed     Abstract available

  208. RAGHAVAKAIMAL A, Cristofanilli M, Tang CM, Alpaugh RK, et al
    CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
    Breast Cancer Res. 2022;24:35.
    PubMed     Abstract available

  209. RALLI GP, Carter RD, McGowan DR, Cheng WC, et al
    Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
    Breast Cancer Res. 2022;24:34.
    PubMed     Abstract available

  210. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
    Breast Cancer Res. 2022;24:29.
    PubMed     Abstract available

  211. ROUSSEAU B, Murugan S, Palagani A, Sarkar DK, et al
    Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
    Breast Cancer Res. 2022;24:33.
    PubMed     Abstract available

  212. ZHENG J, Zhang B
    Biological interpretation of prognostic radiomic score by correlating with tumor heterogeneity and microenvironment.
    Breast Cancer Res. 2022;24:32.

  213. HO WJ, Law AMK, Masle-Farquhar E, Castillo LE, et al
    Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
    Breast Cancer Res. 2022;24:31.
    PubMed     Abstract available

    April 2022
  214. GRINMAN DY, Boras-Granic K, Takyar FM, Dann P, et al
    PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.
    Breast Cancer Res. 2022;24:30.
    PubMed     Abstract available

  215. MINTZ R, Wang M, Xu S, Colditz GA, et al
    Hormone and receptor activator of NF-kappaB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
    Breast Cancer Res. 2022;24:28.
    PubMed     Abstract available

  216. CHEN H, Fan S, Stone J, Thompson DJ, et al
    Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.
    Breast Cancer Res. 2022;24:27.
    PubMed     Abstract available

  217. LIU Z, Liu J, Ebrahimi B, Pratap UP, et al
    SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Breast Cancer Res. 2022;24:26.
    PubMed     Abstract available

  218. FOO SL, Sachaphibulkij K, Lee CLY, Yap GLR, et al
    Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
    Breast Cancer Res. 2022;24:25.
    PubMed     Abstract available

  219. RENAULT AL, Dowty JG, Steen JA, Li S, et al
    Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
    Breast Cancer Res. 2022;24:24.
    PubMed     Abstract available

  220. HEYNEN GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, et al
    Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
    Breast Cancer Res. 2022;24:23.
    PubMed     Abstract available

    March 2022
  221. WON HS, Ahn J, Kim Y, Kim JS, et al
    Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res. 2022;24:22.
    PubMed     Abstract available

  222. TU CF, Li FA, Li LH, Yang RB, et al
    Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.
    Breast Cancer Res. 2022;24:21.
    PubMed     Abstract available

  223. WANG X, Xie T, Luo J, Zhou Z, et al
    Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment.
    Breast Cancer Res. 2022;24:20.
    PubMed     Abstract available

  224. SEMINA SE, Pal P, Kansara NS, Huggins RJ, et al
    Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells.
    Breast Cancer Res. 2022;24:19.
    PubMed     Abstract available

  225. LIU M, Smith R, Liby T, Chiotti K, et al
    INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
    Breast Cancer Res. 2022;24:18.
    PubMed     Abstract available

  226. WATT AC, Goel S
    Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2022;24:17.
    PubMed     Abstract available

  227. GU J, Ternifi R, Larson NB, Carter JM, et al
    Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization.
    Breast Cancer Res. 2022;24:16.
    PubMed     Abstract available

    February 2022
  228. SYRIOPOULOU E, Gasparini A, Humphreys K, Andersson TM, et al
    Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.
    Breast Cancer Res. 2022;24:15.
    PubMed     Abstract available

  229. GASTOUNIOTI A, Desai S, Ahluwalia VS, Conant EF, et al
    Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review.
    Breast Cancer Res. 2022;24:14.
    PubMed     Abstract available

  230. THOMPSON KN, Ju JA, Ory EC, Pratt SJP, et al
    Microtubule disruption reduces metastasis more effectively than primary tumor growth.
    Breast Cancer Res. 2022;24:13.
    PubMed     Abstract available

  231. SUN L, Ding H, Jia Y, Shi M, et al
    Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Breast Cancer Res. 2022;24:12.
    PubMed     Abstract available

  232. WEI G, Teng M, Rosa M, Wang X, et al
    Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Breast Cancer Res. 2022;24:11.
    PubMed     Abstract available

    January 2022
  233. REN Q, Khoo WH, Corr AP, Phan TG, et al
    Gene expression predicts dormant metastatic breast cancer cell phenotype.
    Breast Cancer Res. 2022;24:10.
    PubMed     Abstract available

  234. GECZIK AM, Falk RT, Xu X, Ansong D, et al
    Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study.
    Breast Cancer Res. 2022;24:9.
    PubMed     Abstract available

  235. TANG YH, Rockstroh A, Sokolowski KA, Lynam LR, et al
    Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
    Breast Cancer Res. 2022;24:8.
    PubMed     Abstract available

  236. YIN L, Li Q, Mrdenovic S, Chu GC, et al
    KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
    Breast Cancer Res. 2022;24:7.
    PubMed     Abstract available

  237. DESHPANDE RP, Sharma S, Liu Y, Pandey PR, et al
    LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
    Breast Cancer Res. 2022;24:6.
    PubMed     Abstract available

  238. PIRIKAHU S, Lund H, Cadby G, Wylie E, et al
    The impact of breast density notification on rescreening rates within a population-based mammographic screening program.
    Breast Cancer Res. 2022;24:5.
    PubMed     Abstract available

  239. HJERKIND KV, Johansson ALV, Trewin CB, Russnes HG, et al
    Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.
    Breast Cancer Res. 2022;24:4.
    PubMed     Abstract available

  240. YOON L, Corvalan C, Pereira A, Shepherd J, et al
    Sugar-sweetened beverage consumption and breast composition in a longitudinal study of Chilean girls.
    Breast Cancer Res. 2022;24:3.
    PubMed     Abstract available

  241. MENG L, Chang S, Sang Y, Ding P, et al
    Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
    Breast Cancer Res. 2022;24:1.
    PubMed     Abstract available

  242. AHEARN TU, Zhang H, Michailidou K, Milne RL, et al
    Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
    Breast Cancer Res. 2022;24:2.
    PubMed     Abstract available

    December 2021
  243. NIWINSKA A, Olszewski WP
    The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Breast Cancer Res. 2021;23:118.
    PubMed     Abstract available

  244. SANDSVEDEN M, Borgquist S, Rosendahl AH, Manjer J, et al
    Low thyroid hormone receptor alpha-2 (THRalpha-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.
    Breast Cancer Res. 2021;23:117.
    PubMed     Abstract available

  245. CHEUNG AM, Wang D, Liu K, Hope T, et al
    Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
    Breast Cancer Res. 2021;23:114.
    PubMed     Abstract available

  246. ZHANG M, Meng M, Liu Y, Qi J, et al
    Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
    Breast Cancer Res. 2021;23:116.
    PubMed     Abstract available

  247. LIU S, Chen W, Hu H, Zhang T, et al
    Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2021;23:115.
    PubMed     Abstract available

  248. YAGHOOBI V, Moutafi M, Aung TN, Pelekanou V, et al
    Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
    Breast Cancer Res. 2021;23:113.
    PubMed     Abstract available

  249. GAMPENRIEDER SP, Rinnerthaler G, Tinchon C, Petzer A, et al
    Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
    Breast Cancer Res. 2021;23:112.
    PubMed     Abstract available

  250. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Early-life exposures and age at thelarche in the Sister Study cohort.
    Breast Cancer Res. 2021;23:111.
    PubMed     Abstract available

    November 2021
  251. VIROSTKO J, Sorace AG, Slavkova KP, Kazerouni AS, et al
    Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
    Breast Cancer Res. 2021;23:110.
    PubMed     Abstract available

  252. BOUCHERON P, Anele A, Zietsman A, Galukande M, et al
    Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study.
    Breast Cancer Res. 2021;23:109.
    PubMed     Abstract available

  253. LABRECHE C, Cook DP, Abou-Hamad J, Pascoal J, et al
    Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFbeta/PI3K/AKT pathways.
    Breast Cancer Res. 2021;23:107.
    PubMed     Abstract available

  254. BARBER LE, Zirpoli GR, Cozier YC, Rosenberg L, et al
    Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
    Breast Cancer Res. 2021;23:108.
    PubMed     Abstract available

  255. LIU FC, Veierod MB, Kjaerheim K, Robsahm TE, et al
    Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
    Breast Cancer Res. 2021;23:106.

  256. BODELON C, Mullooly M, Pfeiffer RM, Fan S, et al
    Mammary collagen architecture and its association with mammographic density and lesion severity among women undergoing image-guided breast biopsy.
    Breast Cancer Res. 2021;23:105.
    PubMed     Abstract available

  257. JESSER EA, Brady NJ, Huggins DN, Witschen PM, et al
    STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.
    Breast Cancer Res. 2021;23:104.
    PubMed     Abstract available

  258. HANAMURA T, Christenson JL, O'Neill KI, Rosas E, et al
    Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Breast Cancer Res. 2021;23:102.
    PubMed     Abstract available

  259. COLLIN LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, et al
    Hypoxia-inducible factor-1alpha expression and breast cancer recurrence in a Danish population-based case control study.
    Breast Cancer Res. 2021;23:103.
    PubMed     Abstract available

    October 2021
  260. ROPRI AS, DeVaux RS, Eng J, Chittur SV, et al
    Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Breast Cancer Res. 2021;23:101.
    PubMed     Abstract available

  261. SCHERER SD, Riggio AI, Haroun F, DeRose YS, et al
    An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
    Breast Cancer Res. 2021;23:100.
    PubMed     Abstract available

  262. SAKAGUCHI A, Horimoto Y, Onagi H, Ikarashi D, et al
    Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res. 2021;23:99.
    PubMed     Abstract available

  263. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
    Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
    Breast Cancer Res. 2021;23:97.
    PubMed     Abstract available

  264. CHEN X, Chen DG, Zhao Z, Balko JM, et al
    Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
    Breast Cancer Res. 2021;23:96.
    PubMed     Abstract available

  265. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
    Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:95.
    PubMed     Abstract available

    September 2021
  266. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    PubMed     Abstract available

  267. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    PubMed     Abstract available

  268. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    PubMed     Abstract available

  269. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    PubMed     Abstract available

  270. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    PubMed     Abstract available

  271. YANG L, Wang B, Jiao X, Zhou C, et al
    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Breast Cancer Res. 2021;23:89.
    PubMed     Abstract available

    July 2021
  272. HIS M, Lajous M, Gomez-Flores-Ramos L, Monge A, et al
    Biomarkers of mammographic density in premenopausal women.
    Breast Cancer Res. 2021;23:75.
    PubMed     Abstract available

  273. LU P, Foley J, Zhu C, McNamara K, et al
    Transcriptome and genome evolution during HER2-amplified breast neoplasia.
    Breast Cancer Res. 2021;23:73.
    PubMed     Abstract available

  274. GARZIA NA, Cushing-Haugen K, Kensler TW, Tamimi RM, et al
    Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density.
    Breast Cancer Res. 2021;23:71.
    PubMed     Abstract available

    June 2021
  275. RUTH JR, Pant DK, Pan TC, Seidel HE, et al
    Cellular dormancy in minimal residual disease following targeted therapy.
    Breast Cancer Res. 2021;23:63.
    PubMed     Abstract available

    May 2021
  276. SARRADIN V, Lusque A, Filleron T, Dalenc F, et al
    Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Breast Cancer Res. 2021;23:61.
    PubMed     Abstract available

  277. DE BOER LL, Kho E, Van de Vijver KK, Vranken Peeters MTFD, et al
    Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.
    Breast Cancer Res. 2021;23:59.
    PubMed     Abstract available

  278. CONG L, Maishi N, Annan DA, Young MF, et al
    Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Breast Cancer Res. 2021;23:51.
    PubMed     Abstract available

    April 2021
  279. REIMERS LL, Goldberg M, Tehranifar P, Michels KB, et al
    Benign breast disease and changes in mammographic breast density.
    Breast Cancer Res. 2021;23:49.
    PubMed     Abstract available

  280. YANG HY, Tu CW, Chen CC, Lee CY, et al
    Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience.
    Breast Cancer Res. 2021;23:43.
    PubMed     Abstract available

    February 2021
  281. SZUCS Z, Joseph J, Larkin TJ, Xie B, et al
    Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
    Breast Cancer Res. 2021;23:25.
    PubMed     Abstract available

  282. TIAN J, Wang V, Wang N, Khadang B, et al
    Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
    Breast Cancer Res. 2021;23:23.
    PubMed     Abstract available

    January 2021
  283. ALTOE ML, Kalinsky K, Marone A, Kim HK, et al
    Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
    Breast Cancer Res. 2021;23:16.
    PubMed     Abstract available

  284. BAI F, Liu S, Liu X, Hollern DP, et al
    PDGFRbeta is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Breast Cancer Res. 2021;23:10.
    PubMed     Abstract available

  285. RIEDLINGER GM, Joshi S, Hirshfield KM, Barnard N, et al
    Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
    Breast Cancer Res. 2021;23:7.
    PubMed     Abstract available

  286. MCCART REED AE, Kalinowski L, Simpson PT, Lakhani SR, et al
    Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
    Breast Cancer Res. 2021;23:6.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.